GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells

Yossi CohenDepartment of HematologyAssaf Harofeh Medical Center, Zerifin, Israel, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, IsraelCorrespondence[email protected]

Odit GutweinDepartment of HematologyAssaf Harofeh Medical Center, Zerifin, Israel, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Israel

Osnat Garach-JehoshuaHematology LaboratoryAssaf Harofeh Medical Center, Zerifin, Israel, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Israel

Adina Bar-HaimChemistry DepartmentAssaf Harofeh Medical Center, Zerifin, Israel, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Israel

Abraham KornbergDepartment of HematologyAssaf Harofeh Medical Center, Zerifin, Israel, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Israel

References

Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011;29:1627–33.
PubMed Web of Science ®Google Scholar
Benson DM, Byrd JC. CS1-directed monoclonal antibody therapy for multiple myeloma. J Clin Oncol. 2012;30:2013–5.
PubMed Web of Science ®Google Scholar
Cohen Y, Garach-Jehoshua O, Bar-Haim A, Kornberg A. Niche modulated and niche modulating genes in multiple myeloma. Blood Cancer J. 2012;2:e97.
PubMed Web of Science ®Google Scholar
Atamaniuk J, Gleiss A, Porpaczy E, Kainz B, Grunt TW, Raderer M, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012;42:953–60.
PubMed Web of Science ®Google Scholar
Pilarski LM, Baigorri E, Mant MJ, Pilarski PM, Adamson P, Zola H, et al. Multiple myeloma includes phenotypically defined subsets of clonotypic CD20+ B cells that persist during treatment with rituximab. Clin Med Oncol. 2008;2:275–87.
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date